# OnCo record pancreatic-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/pancreatic-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "pancreatic-roadmap" ;
  schema:name "Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question"@en ;
  schema:alternateName "PDAC roadmap"@en, "Pancreatic ductal adenocarcinoma roadmap"@en, "Pancreatic cancer history"@en, "Pancreatic cancer evidence roadmap"@en ;
  schema:description "Pancreatic cancer has had one operation since 1935 and a handful of chemotherapy drugs since 1997. This roadmap follows the evidence through FOLFIRINOX, chemotherapy before and after surgery, the first inherited-gene drug, the first drugs against the KRAS protein that drives nearly every tumour, personalised vaccines, and the surveillance and blood tests that might catch it earlier, to 2031."@en ;
  schema:url <https://onco.cc/roadmaps/pancreatic-roadmap/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://www.nice.org.uk/guidance/ng85>, <https://www.natcan.org.uk/reports/npaca-state-of-the-nation-report-2026/>, <https://www.natcan.org.uk/reports/npaca-state-of-the-nation-report-2025/>, <https://www.natcan.org.uk/reports/npaca-state-of-the-nation-report-2024/>, <https://www.pancreaticcancer.org.uk/about-us/what-we-do/we-campaign-for-change/>, <https://clinicaltrials.gov/study/NCT04927780>, <https://clinicaltrials.gov/study/NCT04340141> ;
  onco:tag "pancreatic", "gi", "roadmap" ;
  onco:related <https://onco.cc/roadmaps/kras-roadmap/>, <https://onco.cc/roadmaps/early-detection-roadmap/>, <https://onco.cc/roadmaps/surgery-roadmap/>, <https://onco.cc/roadmaps/chemotherapy-roadmap/>, <https://onco.cc/roadmaps/targeted-therapy-roadmap/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/roadmaps/devices-roadmap/>, <https://onco.cc/roadmaps/survivorship-roadmap/>, <https://onco.cc/roadmaps/ctdna-tests/>, <https://onco.cc/pairings/germline-to-parp/>, <https://onco.cc/pairings/g12d-plus-pan-ras/>, <https://onco.cc/ideas/idea-ras-inhibitor-neoadjuvant-pdac/>, <https://onco.cc/ideas/idea-mced-new-onset-diabetes/>, <https://onco.cc/ideas/idea-shared-kras-vaccine-adjuvant/>, <https://onco.cc/collections/nccn/>, <https://onco.cc/collections/pancan/>, <https://onco.cc/ideas/idea-pdac-new-onset-diabetes-risk-score-pathway/>, <https://onco.cc/ideas/idea-pdac-surveillance-for-every-germline-carrier/>, <https://onco.cc/ideas/idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease/>, <https://onco.cc/ideas/idea-pdac-stromal-reprogramming-not-depletion/>, <https://onco.cc/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/>, <https://onco.cc/ideas/idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials/>, <https://onco.cc/ideas/idea-pdac-enzyme-replacement-prescribing-by-default/>, <https://onco.cc/ideas/idea-pdac-uk-active-treatment-rate-audit-and-target/>, <https://onco.cc/ideas/idea-pdac-uk-fast-track-diagnosis-to-treatment-pathway/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/borderline-resectable-pdac/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/brca-palb2-pdac/> ;
  onco:sections <https://onco.cc/fronts/surgery/>, <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/early-detection/>, <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/ttfields/>, <https://onco.cc/technologies/mced/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/pancreatic-surveillance/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/technologies/wes-wgs/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/fap/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/drugs/liposomal-irinotecan/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/drugs/eli-002-7p/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/drugs/ponsegromab/> ;
  onco:companies <https://onco.cc/companies/unicancer/>, <https://onco.cc/companies/revolution-medicines/>, <https://onco.cc/companies/ipsen/>, <https://onco.cc/companies/novocure/>, <https://onco.cc/companies/biontech/>, <https://onco.cc/companies/elicio-therapeutics/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:institutions <https://onco.cc/institutions/esmo/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/cruk/>, <https://onco.cc/institutions/mayo-clinic/>, <https://onco.cc/institutions/johns-hopkins/>, <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/erasmus-mc/>, <https://onco.cc/institutions/garvan-institute/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/ddr/> ;
  onco:terms <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/desmoplasia/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/ppv/> ;
  onco:trials <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/espac-4/>, <https://onco.cc/trials/espac-5/>, <https://onco.cc/trials/conko-001/>, <https://onco.cc/trials/lap07/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/trials/napoli-3/>, <https://onco.cc/trials/polo/>, <https://onco.cc/trials/panova-3/>, <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/trials/amplify-7p/>, <https://onco.cc/trials/precede/>, <https://onco.cc/trials/nct05968326/>, <https://onco.cc/trials/nct07491445/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/nct07805954/>, <https://onco.cc/trials/nct07522073/>, <https://onco.cc/trials/nct07262567/> ;
  onco:people <https://onco.cc/people/thierry-conroy/>, <https://onco.cc/people/daniel-von-hoff/>, <https://onco.cc/people/eileen-oreilly/>, <https://onco.cc/people/talia-golan/>, <https://onco.cc/people/zev-wainberg/>, <https://onco.cc/people/vinod-balachandran/>, <https://onco.cc/people/kevan-shokat/>, <https://onco.cc/people/marc-besselink/>, <https://onco.cc/people/eric-van-cutsem/>, <https://onco.cc/people/anirban-maitra/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-early-detection/>, <https://onco.cc/bottlenecks/b-hereditary-risk/>, <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-tme-immunosuppression/>, <https://onco.cc/bottlenecks/b-cachexia-supportive/>, <https://onco.cc/bottlenecks/b-surgery-radiation-innovation/>, <https://onco.cc/bottlenecks/b-aging-comorbidity/>, <https://onco.cc/bottlenecks/b-care-fragmentation/>, <https://onco.cc/bottlenecks/b-negative-results/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-knowledge-diffusion/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-whipple-carcinoma-ampulla-of-vater-ann-surg-1935/>, <https://onco.cc/key-papers/paper-traverso-longmire-pylorus-preservation-pancreaticoduodenectomy-sgo-1978/>, <https://onco.cc/key-papers/paper-tempero-ca19-9-lewis-antigens-cancer-res-1987/>, <https://onco.cc/key-papers/paper-almoguera-kras-codon-12-pancreatic-cell-1988/>, <https://onco.cc/key-papers/paper-burris-gemcitabine-pancreatic-jco-1997/>, <https://onco.cc/key-papers/paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004/>, <https://onco.cc/key-papers/paper-chari-pancreatic-cancer-following-diabetes-gastroenterology-2005/>, <https://onco.cc/key-papers/paper-conko-001-adjuvant-gemcitabine-observation-jama-2007/>, <https://onco.cc/key-papers/paper-hidalgo-pancreatic-cancer-review-nejm-2010/>, <https://onco.cc/key-papers/paper-conroy-folfirinox-pancreatic-nejm-2011/>, <https://onco.cc/key-papers/paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013/>, <https://onco.cc/key-papers/paper-ostrem-kras-g12c-nature-2013/>, <https://onco.cc/key-papers/paper-ozdemir-caf-depletion-accelerates-pancreatic-cancer-cancer-cell-2014/>, <https://onco.cc/key-papers/paper-waddell-whole-genomes-pancreatic-nature-2015/>, <https://onco.cc/key-papers/paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015/>, <https://onco.cc/key-papers/paper-bailey-molecular-subtypes-pancreatic-nature-2016/>, <https://onco.cc/key-papers/paper-napoli-1-nanoliposomal-irinotecan-lancet-2016/>, <https://onco.cc/key-papers/paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018/>, <https://onco.cc/key-papers/paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018/>, <https://onco.cc/key-papers/paper-canto-caps-long-term-surveillance-gastroenterology-2018/>, <https://onco.cc/key-papers/paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018/>, <https://onco.cc/key-papers/paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019/>, <https://onco.cc/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/>, <https://onco.cc/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/>, <https://onco.cc/key-papers/paper-halo-301-pegvorhyaluronidase-jco-2020/>, <https://onco.cc/key-papers/paper-caps-consortium-surveillance-recommendations-gut-2020/>, <https://onco.cc/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/>, <https://onco.cc/key-papers/paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021/>, <https://onco.cc/key-papers/paper-fahrmann-ca19-9-lead-time-gastroenterology-2021/>, <https://onco.cc/key-papers/paper-rahib-projection-us-cancer-2040-jama-netw-open-2021/>, <https://onco.cc/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/>, <https://onco.cc/key-papers/paper-dbouk-caps5-stage-survival-jco-2022/>, <https://onco.cc/key-papers/paper-napoli-3-lancet-2023/>, <https://onco.cc/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/>, <https://onco.cc/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/>, <https://onco.cc/key-papers/paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024/>, <https://onco.cc/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/>, <https://onco.cc/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/>, <https://onco.cc/key-papers/paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025/>, <https://onco.cc/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/>, <https://onco.cc/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/>, <https://onco.cc/key-papers/paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019/> .